Directed by microarray analyses, we report that autocrine human growth hormone (hGH) increased the mRNA and protein expression of DNA methyltransferase 1 (DNMT1), DNMT3A and DNMT3B in mammary carcinoma cells. Autocrine hGH stimulation of DNMT3A and DNMT3B expression was mediated by JAK2 and Src kinases, and treatment of mammary carcinoma cells with the DNMT inhibitor, 5 0 -aza-2 0 -deoxycytidine (AZA), abrogated autocrine hGH-stimulated cellular proliferation, apoptosis and anchorage-independent growth. AZA reversed the epitheliomesenchymal transition of mammary carcinoma cells induced by autocrine hGH, to an epithelioid morphology and abrogated cell migration stimulated by autocrine hGH. Autocrine hGH-stimulated hypermethylation of the first exon of the PLAKOGLOBIN gene and AZA abrogated the ability of autocrine hGH to repress plakoglobin gene transcription. Small interfering RNA (siRNA)-mediated depletion of the individual DNMT molecules did not release autocrine hGH repression of PLAKOGLOBIN promoter activity nor did individual DNMT depletion affect autocrine hGH-stimulated migration. However, concomitant siRNA-mediated depletion of both DNMT3A and DNMT3B abrogated hypermethylation of the PLAKO-GLOBIN gene stimulated by autocrine hGH and subsequent repression of plakoglobin gene transcription and increased cell migration. Thus, the autocrine hGHstimulated increases in DNMT3A and DNMT3B expression mediate repression of plakoglobin gene transcription by direct hypermethylation of its promoter and consequent phenotypic conversion of mammary carcinoma cells. Autocrine hGH, therefore, utilizes DNA methylation as a mechanism to exert its oncogenic effects in mammary carcinoma cells.
Introduction
DNA methylation is one epigenetic modification of the genome essential for mammalian embryonic development (Li et al., 1992a) , X-chromosome inactivation (Jaenisch et al., 1998) , genomic imprinting (Bartolomei and Tilghman, 1997) and silencing of parasitic transposable elements (Waterhouse et al., 2001) . DNA methylation also plays a major role in the development and progression of cancer through transcriptional repression of essential growth regulator genes (Baylin, 2005) . In the mammalian genome, methylation occurs at the 5 0 position of the cytosine in the CpG dinucleotide sequence. CpG sequences are sometimes found as discreet clusters called CpG islands, often found in the 5 0 -region of genes (Baylin, 2005) . There are three functional DNA methyltransferases (DNMTs) namely DNMT1, DNMT3A and DNMT3B. DNMT1 maintains pre-existing methylation patterns in the genome and preferentially methylates hemimethylated DNA (Bestor et al., 1988) , whereas DNMT3A and DNMT3B function as de novo methyltransferases by methylation of unmethylated and hemimethylated DNA with equal efficiency (Okano et al., 1999) .
Elevated autocrine hGH expression is associated with oncogenicity of mammary epithelial cells (Zhu et al., 2005) and neoplastic progression (Perry et al., 2006) . Production of autocrine hGH has also been demonstrated to stimulate the phenotypic conversion of mammary epithelial cells towards the morphological and molecular characteristics of a mesenchymal cell, including expression of fibronectin and vimentin, and loss of plakoglobin expression (Mukhina et al., 2004) . Plakoglobin is a component of the adherens junctions complex, and is a multifunctional protein involved in cell-cell adhesion and transcriptional regulation (Fukunaga et al., 2005) . Loss of plakoglobin expression results in dissolution of adherens junctions and has been associated with neoplastic progression and tumour invasion (Savagner, 2001; Mukhina et al., 2004) . Repression of plakoglobin expression is one mechanism by which autocrine hGH executes phenotypic conversion of mammary carcinoma cells (Mukhina et al., 2004) . However, the precise mechanism mediating autocrine hGH repression of plakoglobin expression in mammary carcinoma cells has not been determined.
Recently, loss of plakoglobin expression through CpG methylation of the first exon of the PLAKOGLOBIN gene promoter was reported to be associated with the pathogenesis of prostate cancer . Methylation of the PLAKOGLOBIN gene has also been reported to be associated with a poor prognosis in renal cell carcinoma . CpG hypermethylation of the plakoglobin promoter has also been demonstrated to be responsible for the loss of plakoglobin expression in thyroid and lung cancer (Potter et al., 2001; Winn et al., 2002) . Increased expression of DNMT1, DNMT3A and DNMT3B has been reported in many cancers (el-Deiry et al., 1991; Belinsky et al., 1996; Robertson et al., 1999) . However, little is known regarding the regulation of DNMTs by trophic factors in neoplasia and the molecular mechanisms mediating DNA methylation in cancer remains largely undefined.
Herein, we report that autocrine hGH stimulated the expression of DNMT1, DNMT3A and DNMT3B in human mammary carcinoma cells. Autocrine hGH regulation of DNMTs is mediated by JAK2 and Src kinases, and inhibition of methylation reversed the epitheliomesenchymal transition of mammary carcinoma cells stimulated by autocrine hGH. 5 0 -Aza-2 0 -deoxycytidine (AZA) also abrogated autocrine hGH stimulated oncogenicity of mammary carcinoma cells. Small interfering RNA (siRNA)-mediated depletion of DNMT3A and DNMT3B specifically increased PLAKOGLOBIN gene promoter activity and expression, and subsequently abrogated autocrine hGH stimulated mammary carcinoma cell migration. Thus, autocrine hGH utilizes DNA methylation as a mechanism to execute its oncogenic potential in mammary carcinoma cells.
Results
Autocrine hGH increases the expression and activity of DNMT1, DNMT3A and DNMT3B Based on previous microarray studies (Mertani et al., 2001) , we examined the expression and activity of the functional DNMTs in human mammary carcinoma cells (MCF-7) stably transfected with either the hGH gene (MCF-hGH) or a translation-deficient hGH gene (MCF-MUT). Figure 1a illustrates amplified fragments of the predicted size appropriate for DNMT1 (102 bp), DNMT3A (110 bp) and DNMT3B (112 bp) mRNA in MCF-MUT (MUT) and MCF-hGH (hGH) cells. DNMT1, DNMT3A and DNMT3B mRNA transcripts were all increased in MCF-hGH cells compared with MCF-MUT cells. The level of b-actin mRNA was equal in both cell lines and was used as an internal control ( Figure 1a) .
We next examined the effect of autocrine hGH on the activity of the 5 0 -promoter regions of the DNMT3A and DNMT3B genes in MCF-MUT and MCF-hGH cells using reporter plasmids containing the human DNMT3A first and second promoter (DNMT3A-P1 þ P2) which spans from nucleotide À2489 to þ 640, DNMT3A third promoter (DNMT3A-P3) which spans from nucleotide À3007 to þ 1021 and the DNMT3B promoter (DNMT3B-P1) which spans from À2483 to þ 309. As observed in Figure 1b , both DNMT3A promoters displayed a 2-fold increase in activity in MCF-hGH cells compared with MCF-MUT cells. DNMT3B-P1 also exhibited a significant increase in activity in MCF-hGH cells compared with MCF-MUT cells.
To determine if the increase in DNMT mRNA levels observed in MCF-hGH cells correlated with increased protein levels, we examined DNMT1, DNMT3A and DNMT3B protein expression in MCF-MUT and MCFhGH cells. We observed an increased protein level of all three DNMTs in MCF-hGH cells compared with MCF-MUT cells (Figure 1c) . Examination of the total cellular enzymatic activity of DNMT demonstrated that autocrine hGH production in MCF-hGH cells increased DNMT activity compared with the control MCF-MUT cells (Figure 1d ). However, this increased DNMT activity did not correlate with alteration of global DNA methylation in MCF-hGH cells compared with MCF-MUT (Figure 1e ), suggestive that autocrine hGH does not affect the overall global methylation of the genome.
Autocrine hGH regulation of DNMT3A and DNMT3B is mediated by JAK2 and c-Src Both JAK2 and c-Src are concomitantly activated following GH binding to its receptor (Ling et al., 2003) . To determine the relative contribution of JAK2 and c-Src in the autocrine hGH-stimulated increase in DNMT1, DNMT3A and DNMT3B expression, we examined the mRNA expression levels of DNMT1, DNMT3A and DNMT3B in MCF-MUT and MCFhGH cells treated with pharmacological inhibitors of JAK2 namely AG490, or Src kinases namely PP1 or PP2. We also utilized the inactive structural analogue PP3 as control in the experiments. Figure 2a illustrates that expression of DNMT1 in MCF-MUT and MCFhGH cells is not affected in the presence of AG490. In contrast, the autocrine hGH-stimulated expression of DNMT3A and DNMT3B was abrogated in the presence of AG490 (Figure 2a ). Both the basal and autocrine hGH-stimulated mRNA expression of DNMT1, DNMT3A and DNMT3B in MCF-MUT and MCF-hGH cells were abrogated after treatment with PP1 and PP2, but unaffected in presence of the inactive analogue PP3 (Figure 2b) . Thus, the autocrine hGH regulation of DNMT3A and DNMT3B gene expression is mediated by both JAK2 and Src family of proteins whereas autocrine hGH regulation of DNMT1 gene expression is exclusively regulated by Src kinases in human mammary carcinoma cells.
We next examined autocrine hGH activation of the human DNMT3A and DNMT3B gene promoters namely DNMT3A-P1 þ P2 (Figures 3a and b) , DNMT3A-P3 (Figures 3c and d ) and DNMT3B-P1 (Figures 3e and f) , respectively. Autocrine hGH increased the transient promoter activity of DNMT3A-P1 þ P2 and treatment with PP1, PP2 and AG490 notably decreased both basal and autocrine hGH-stimulated activity of DNMT3A-P1 þ P2 DNMT3A and DNMT3B repress plakoglobin gene expression F Shafiei et al ( Figure 3a) . Similarly, autocrine hGH-stimulated activity of DNMT3A-P1 þ P2 was decreased by co-transfection of dominant negative expression vectors for c-Src (c-Src dn ) and JAK2 (JAK2 dn ) (Figure 3b ). In contrast, autocrine hGHstimulated activity of the DNMT3A-P3 promoter was not affected by either AG490 or JAK2 dn (Figures 3c and d) but decreased in the presence of PP1, PP2 or c-Src dn , suggesting that regulation of this 5 0 -region of DNMT3A is independent of JAK2, and perhaps exclusively regulated by the Src family of kinases. In the case of DNMT3B, autocrine hGHstimulated activity of DNMT3B-P1 was notably decreased in the presence of PP1, PP2 and AG490 (Figure 3e ) as well as c-Src dn -and JAK2 dn -transfected cells (Figure 3f ). Therefore, autocrine hGH regulation of DNMT3A and DNMT3B gene transcription is mediated by both JAK2 and Src family of proteins in mammary carcinoma cells.
Autocrine hGH utilizes DNA methylation to stimulate the oncogenicity of mammary carcinoma cells To determine whether autocrine hGH utilizes DNA methylation to increase the oncogenicity of mammary carcinoma cells, we determined the effect of AZA on the ability of autocrine hGH to stimulate proliferation, survival and anchorage-independent growth of mammary carcinoma cells. (Figure 4c ). Inhibition of DNMT activity therefore abrogated the ability of autocrine hGH to stimulate proliferation and survival and therefore increases in mammary carcinoma cell number.
Given that a characteristic of oncogenicity is the capacity for anchorage-independent growth (Savagner, 2001) , we also examined the effect of AZA on hGHstimulated anchorage-independent growth of mammary Figure 4d , autocrine hGH production resulted in a 2.5-fold increase in the number of colonies formed in soft agar after 14 days. AZA specifically abrogated autocrine hGH-stimulated soft agar colony formation in MCF-hGH cells whereas treatment of MCF-MUT cells with AZA did not alter soft agar colony formation (Figure 4d ). Autocrine hGHstimulated oncogenicity of mammary carcinoma cells is therefore dependent on DNMT activity.
Inhibition of methylation reverses the phenotypic conversion of mammary carcinoma cells and acquisition of an invasive phenotype induced by autocrine hGH
We have previously demonstrated that autocrine production of hGH by MCF-7 cells dramatically altered their cellular morphology such that they lose their epithelial characteristics and acquire a mesenchymal-like morphology (Mukhina et al., 2004) . We therefore examined the cellular morphology of MCF-MUT and MCF-hGH cells in the absence or presence of AZA. MCF-MUT cells which exhibit epithelial characteristics similar to the parental MCF-7 cell line (data not shown) displayed minimal change in cellular morphology in the presence of AZA. In contrast, MCF-hGH cells which exhibited a mesenchymal-like phenotype with formation of multiple cellular protrusions reverted to an epithelioid morphology with clear round shaped epithelial cells (as indicated by red arrow) after treatment with AZA ( Figure 5a ). We next investigated the consequence of reversion of cellular morphology of mammary carcinoma cells by AZA on the ability of MCF-MUT and MCF-hGH cells to migrate through transwell chambers. As observed in Figure 5b , MCF-hGH cells migrated through transwell chamber pores at a dramatically higher rate than MCF-MUT cells similar to that previously reported (Mukhina et al., 2004) . Treatment of MCF-hGH cells with AZA significantly reduced the migration of MCF-hGH cells to levels observed in MCF-MUT cells, whereas AZA did not alter the rate of migration in MCF-MUT cells (Figures 5b and c) . Thus, AZA reversed the phenotypic conversion of mammary carcinoma cells induced by autocrine hGH with resultant abrogation of the autocrine hGH-stimulated migration of mammary carcinoma cells.
Inhibition of methylation releases autocrine hGH repression of plakoglobin gene expression
Hypermethylation of the first exon of the PLAKOGLO-BIN gene has been recently linked to loss of plakoglobin expression in human prostate cancer . We have previously demonstrated that epitheliomesenchymal transition of mammary carcinoma cells by (Figure 6c ). Autocrine hGH therefore stimulates methylation of CpGs of the first exon in the plakoglobin promoter. Next, we examined whether autocrine hGH leads to transcriptional repression of the PLAKOGLOBIN gene. We therefore examined the activity of the 5 0 -flanking promoter region of human PLAKOGLOBIN gene encoding nucleotides À297 to þ 61, in MCF-MUT and MCF-hGH cells. As demonstrated in Figure 6d , there was a significant decrease in PLAKOGLOBIN promoter activity observed in MCF-hGH cells compared with MCF-MUT cells indicative that the promoter is repressed as a result of autocrine hGH production. Treatment of MCF-hGH cells with AZA released the promoter activity repressed by autocrine hGH. Treatment with AZA also increased the promoter activity of PLAKOGLOBIN in MCF-MUT cells (Figure 6d ). To Concomitant depletion of DNMT3A and DNMT3B abrogated autocrine hGH repression of plakoglobin gene transcription We generated siRNA constructs of human DNMT1, DNMT3A and DNMT3B to target each endogenous DNMT molecule for depletion and examined the activity of PLAKOGLOBIN gene promoter per se. For control purposes we utilized the same vector with a scrambled siRNA target sequence. The ability of each of the siRNA constructs to deplete DNMT1, DNMT3A and DNMT3B was confirmed by RT-PCR and western blot analysis in MCF-7 cells with b-actin detected as loading control (Figures 7a and b, respectively) . We examined the activity of the PLAKOGLOBIN gene promoter in MCF-7-MUT and MCF-hGH cells transiently cotransfected with siRNA constructs for scrambled vector (control siRNA), DNMT1 siRNA, DNMT3A siRNA and DNMT3B siRNA, alone or in combination (Figure 7c ). siRNA-mediated depletion of the individual DNMT molecules did not revert PLAKOGLOBIN promoter activity in MCF-MUT and MCF-hGH cells. However, abrogation of the repression of PLAKOGLO-BIN promoter activity by autocrine hGH was observed with concomitant siRNA-mediated depletion of both DNMT3A and DNMT3B (Figure 7c ). The combined depletion of DNMT1, DNMT3A and DNMT3B did not further increase PLAKOGLOBIN promoter activity compared with concomitant depletion of DNMT3A and DNMT3B. The combined depletion of DNMT1 with either DNMT3A or DNMT3B also did not significantly increase plakoglobin promoter activity (data not shown), indicative that autocrine hGH repression of PLAKOGLOBIN promoter activity is mediated via the combined action of DNMT3A and DNMT3B.
We also determined the functional significance of restoration of plakoglobin gene transcription following concomitant depletion of DNMT3A and DNMT3B transcription. We observed that individual depletion of DNMT1, DNMT3A or DNMT3B did not abrogate autocrine hGH-stimulated migration of MCF-hGH cells (Figure 7d ). However, concomitant depletion of DNMT3A and DNMT3B dramatically abrogated the ability of MCF-hGH cells to migrate through the transwell chamber. Thus, depletion of DNMT3A and DNMT3B expression resulted in abrogation of autocrine hGH-stimulated migration of mammary carcinoma cells.
We next investigated whether release of autocrine hGH repression of plakoglobin gene transcription by DNMT3A and DNMT3B siRNA constructs was a direct consequence of changes in the methylation status of the PLAKOGLOBIN promoter. Genomic DNA was extracted from MCF-MUT and MCF-hGH cells transiently transfected with siRNA constructs for DNMT3A and DNMT3B in combination or scrambled vector (control siRNA), and after bisulphite treatment, subjected to MS-PCR using the PG-M primer sets which detects methylated alleles of PLAKOGLOBIN promoter (Figure 7e ). We observed decreased levels of methylated CpG in both MCF-MUT and MCF-hGH cells following concomitant depletion of DNMT3A and DNMT3B, compared with the control siRNA (Figure 7e ). Thus, depletion of DNMT3A and DNMT3B expression resulted in decreased methylation of PLAKOGLOBIN promoter in mammary carcinoma cells.
Discussion
There is ample evidence for a role of DNA methylation in gene silencing in cancer (Jones, 2002; Baylin, 2005) . However, little is known regarding regulation of DNMTs by trophic or oncogenic factors and the underlying signalling mechanisms mediating DNMT expression and aberrant methylation patterns in cancer. Aberrant DNA methylation has been reported to affect many cellular processes, including transcriptional regulation (Herman, 1999) , differentiation (Cameron et al., 1999) and apoptosis (Hodge et al., 2005) . In the present study, we have demonstrated that autocrine hGHstimulated EMT in mammary carcinoma cells is executed by DNMT3A-and DNMT3B-mediated hypermethylation of the plakoglobin promoter. Autocrine interleukin-6 (IL-6) has been reported to stimulate the expression and activity of DNMT1 (Hodge et al., 2001) , and recently demonstrated to repress p53 gene transcription by hypermethylation of its promoter region in a human multiple myeloma cell line (Hodge et al., 2005) . Autocrine IL-6 production in cholangiocarcinoma cells also produced resistance to the inhibitory effects of AZA on cell proliferation and soft agar colony formation (Wehbe et al., 2006) associated with altered promoter methylation of several genes. Furthermore, IL-6 epigenetically regulates a number of microRNAs to influence oncogenicity of cholangiocarcinoma cells (Meng et al., 2007) . The receptors for both IL-6 and hGH belong to the cytokine receptor superfamily (Waters et al., 1999) and utilize similar signal transduction mechanisms including the JAK pathway (Zhu et al., 2002) demonstrated herein to regulate DNMT expression. In another report, nerve growth factor (NGF) stimulated the expression of DNMT3B and induced the differentiation of PC12 cells into neuronal cells. Interestingly, NGFstimulated DNMT3B expression downregulated the expression of DNMT1 and DNMT3A, suggestive that DNMT3B alone possesses a specific role in NGFmediated neuronal differentiation (Bai et al., 2005) . Growth factor utilization of a methylation dependent DNMT3A and DNMT3B repress plakoglobin gene expression F Shafiei et al signalling mechanism may therefore represent a convergence of pathways used to regulate gene expression. We have previously demonstrated such interaction of epigenetic mechanisms with cytokine signal transduction pathways. RhoA-dependent enhancement of GH-stimulated, Stat5-mediated transcription was due to repression of histone deacetylase 6 activity recruited by transcription cofactor p300 that negatively regulates GH-stimulated, Stat5-mediated transcription (Ling and Lobie, 2004) . Cytokines and other pro-oncogenic growth factors may therefore utilize epigenetic pathways including methylation as one mechanism to regulate downstream target genes essential for cell survival, proliferation and oncogenicity. In this regard, it is tempting to speculate that aberrant methylation patterns in cancer may simply reflect the activity of the particular trophic factor(s) used to drive that particular tumour. Aberrant methylation would therefore be a secondary event to a higher order oncogenic stimulation and not necessarily be causally associated with oncogenic transformation. Indeed, a large number of genes regulated by AZA in cholangiocarcinoma cells are also co-regulated by IL-6 (Wehbe et al., 2006) . However, evidence to support this speculative hypothesis requires further empirical testing and analyses. Herein, we have demonstrated that concomitant depletion of de novo methylation capacity released autocrine hGH repression of plakoglobin expression and abrogated motility of mammary carcinoma cells. We also observed that concomitant depletion of DNMT3A and DNMT3B mimicked the effect of AZA in releasing plakoglobin gene transcription and subsequent abrogation of mammary carcinoma cell migration. This is consistent with a recent report demonstrating that AZA mediates its effect through the concomitant inhibitory actions of DNMT3A and DNMT3B (Oka et al., 2005) . We have also demonstrated that autocrine hGH repression of plakoglobin gene transcription is a direct consequence of hypermethylation of its promoter in mammary carcinoma cells which can be released by depletion of DNMT3A and DNMT3B. Depletion of DNMT3A and DNMT3B has been recently reported to abrogate the migration and invasion of trophoblastic cells, through restoration of plakoglobin gene expression (Rahnama et al., 2006) , further support for the specific role of DNMT3A and DNMT3B in plakoglobin gene repression.
Given that autocrine hGH stimulation of DNMT3A and DNMT3B was inhibited by c-Src, it is likely that repression of plakoglobin expression by autocrine hGH is mediated in a c-Src-DNMT3A-DNMT3B manner. It has been previously demonstrated that selective inhibition of Src kinases abrogated the increased cell migration stimulated by autocrine hGH (Mukhina et al., 2004) . Inhibition of Src kinases also abrogated autocrine hGH repression of plakoglobin. Recently, Sung et al. (2005) , observed significant upregulation of DNMT1 expression in v-Src-transfected 3Y1 rat fibroblasts versus mock-transfected cells identifying a predominant role for Src kinases in DNMT1 regulation (Sung et al., 2005) . Src, in conjunction with JAK kinases, may therefore be major upstream cellular pathways regulating the expression of the DNMTs and subsequent methylation. Src also has a well-known oncogenic role and is activated by multiple cytokines including IL-6 (Hausherr et al., 2007) .
In conclusion, we have demonstrated that autocrine hGH reduces plakoglobin gene expression by CpG hypermethylation of its promoter dependent on DNMT3A and DNMT3B. Autocrine hGH therefore utilizes DNA methylation as one mechanism to stimulate oncogenicity and phenotypic conversion of mammary carcinoma cells.
Materials and methods
Cell culture MCF-7 cells were obtained from the American Type Culture Collection. MCF-hGH expressing wild-type hGH gene and its cognate control MCF-MUT were established and cultured as previously described (Kaulsay et al., 1999) .
Reporter plasmids
The reporter plasmids containing full-length human DNMT3A first þ second promoters pGL3A-P1 þ 2 (À2489/ þ 640), DNMT3A third promoter pGL3A-P3 (À3007/ þ 1021) and DNMT3B first promoter pGL3B-P1 (À2483/ þ 309) was a gift from Dr Yanagisawa (Yanagisawa et al., 2002) . The PLA-KOGLOBIN promoter pGL-Pg5 (À297/ þ 61) was a gift from Dr Brabant (Potter et al., 2001) . The dominant negative c-Src was a gift from Dr Brugge (Nemeth et al., 1989) and JAK2 was a gift from Dr Silvennoinen (Saharinen et al., 2000) .
Cell biology assays DNMT activity was determined as previously described (Issa et al., 1993) , and normalized to protein levels. Anchorageindependent growth assays, including suspension culture, were performed as previously described (Zhang et al., 2003) . Entry to S-phase was determined by the nuclear incorporation of BrdU as previously described (Kaulsay et al., 2001) . Apoptotic cell death was measured by fluorescent microscopic analysis after staining with Hoechst 33258, as previously described (Kaulsay et al., 2001) . Migration assays were performed in transwell culture chambers from Corning (Life Sciences, Lowell, MA, USA) according to the manufacturer's instructions, and as previously described (Mukhina et al., 2004) . Confocal laser-scanning microscopy including visualization of filamentous-actin was performed as previously described (Rahnama et al., 2006) . Western blot analysis for DNMT1, DNMT3A and DNMT3B was performed as described by Rahnama et al. (2006) and for PLAKOGLOBIN by Mukhina et al. (2004) .Where appropriate cells were cultured in the presence of vehicle or 5 mM AZA (Sigma, St. Louis, MO, USA) for 24-48 h. Cell viability was determined by Trypan blue exclusion.
RNA and PCR
Total RNA was isolated using TRIZOL (Invitrogen, NZ), according to the manufacturer's instructions. RT-PCR was performed using One-Step RT-PCR (Qiagen, Valencia, CA, USA). Sequences of the primers for amplification of mRNA fragments are listed in Supplementary Table 1 (see Supplementary data). For MS-PCR genomic DNA was isolated using the Wizard Genomic DNA Purification Kit (Promega, Madison, WI, USA). Bisulphite treatment of DNA was carried out according to the manufacturer's instructions (EZ DNA Methylation-Gold Kit; Zymo Research, Orange, CA, USA). The resulting bisulphite-modified DNA was amplified by PCR using the primers sequences listed in Supplementary Table 1 and PCR conditions as previously described (Potter et al., 2001) .
Construction of small interfering RNA expression vectors
Please see Supplementary data.
Cell transfection and luciferase assay Cells were transiently transfected with expression vector containing the gene promoters for DNMT3A, DNMT3B, PLAKOGLOBIN or siRNA vectors. Saint-Mix (Synvolux Therapeutics BV, Groningen, The Netherlands) transfection reagent was used according to the manufacturer's instructions and cultured in RPMI-1640 containing 1% fetal bovine serum, and normalized with respect to b-galactosidase activity.
Global DNA methylation analysis Global DNA methylation was determined based on the method by Serrano et al. (1993) , with the following modifications;
Iododeoxycytidine was used as the internal standard, Waters 2695 autosampler and W2487 UV detector were used in conjunction with Millenium32 chromatography manager software (Waters Corporation, Milford, MA, USA) . A Luna C18(2) 250 Â 4.6 mm 3 mm column (Phenomenex, Auckland, New Zealand) was utilized, with a gradient of increasing percentage MeCN (4-40%) and constant concentration of ammonium acetate (50 mM, pH 5.3). Quantification of all bases was determined at 280 nm. All determinations are carried with samples from two quality control pools with the mean global methylation percentage and CV% for bacterial (mean: 0.936% CV: 6.09%), and fetal sheep tissue (mean 4.2% CV: 1.21%).
